Natural killer cell activity in metastatic castration resistant prostate cancer patients treated with enzalutamide

Metastatic castration resistant prostate cancer (mCRPC) is still the lethal stage for the whole spectrum of prostate cancer disease. Even though different treatment options have been introduced in the last decade with a significant survival improvement for this population, a lack of more reliable pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Zedan, A. H., Nederby, L., Volmer, L. M., Madsen, C. V., Sørensen, B. E., Hansen, T. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564750/
https://www.ncbi.nlm.nih.gov/pubmed/37816781
http://dx.doi.org/10.1038/s41598-023-43937-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10564750/
https://www.ncbi.nlm.nih.gov/pubmed/37816781
http://dx.doi.org/10.1038/s41598-023-43937-7

Ejemplares similares